IQVIA said revenues in 2024 increased $421 million or 2.8% compared to 2023. Constant currency revenue growth was approximately $510 million or 3.4%, comprised of an increase of $333 million in Technology & Analytics Solutions, $167 million in Research & Development Solutions, and $10 million in Contract Sales & Medical Solutions.

1. 01

   IQVIA said revenues in 2024 increased $421 million or 2.8% compared to 2023. Constant currency revenue growth was approximately $510 million or 3.4%, comprised of an increase of $333 million in Technology & Analytics Solutions, $167 million in Research & Development Solutions, and $10 million in Contract Sales & Medical Solutions.

2. 02

   The company said Research & Development Solutions' contracted backlog increased from $29.7 billion as of December 31, 2023 to $31.1 billion as of December 31, 2024, and it expects approximately $7.9 billion of this backlog to convert to revenues in the next 12 months.

3. 03

   IQVIA said cash provided by operating activities in 2024 increased $567 million compared to 2023, citing as factors an increase in cash from accounts receivable and unbilled services of $570 million and an increase in cash-related net income of $129 million. The company added that more cash used for accounts payable and accrued expenses of $152 million partially offset this increase.

4. 04

   The company said as of December 31, 2024 cash and cash equivalents were $1,702 million, total indebtedness was $14,045 million, and additional available borrowings under the revolving credit facility were $1,170 million. It added that as of the same date, remaining authorization to repurchase common stock under the Repurchase Program was $1,013 million.

Key figures

Fiscal year ended December 31, 2024

Revenue

$15.4B

Operating income

$2.2B

Net income

$1.4B

EPS

$7.49

Operating cash flow

$2.7B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.